Phision Therapeutics eyes up UCD start-up award

Dr Breandan Kennedy and Dr Alison Reynolds, UCD School of Biomolecular and Biomedical Science & the UCD Conway Institute

19 November 2015

Phision Therapeutics, an early-stage life sciences venture, has won University College Dublin’s (UCD) VentureLaunch Accelerator Programme start-up award.

In addition to the 2015 UCD VentureLaunch Accelerator award, Phision was presented with a cheque for €10,000, and a professional services package to the value of €15,000.

Phision is developing proprietary therapeutic drugs to more effectively treat vision loss to prevent blindness associated with ageing or diabetes.

The retinal disease age-related macular degeneration (AMD) is a leading cause of vision loss in Western societies. In the US alone the retinal therapeutic market, to treat such diseases, is valued at $3.5 billion annually.

The current treatment for patients experiencing vision loss due to AMD involves up to 12 eye injections per year. It is recognised that patients are also at risk of eye infections or retinal detachments due to the injections. In addition up to 30% of AMD patients do not respond to these injections, and for them there is currently no effective alternative treatment.

To address such issues and using an unbiased, systems-pharmacology approach Phision Therapeutics has identified, and is developing, small molecule drugs with novel mechanisms of action to curb the undesired growth of ‘leaky’ new blood vessels in the eye which lead to vision loss and blindness.

Phision Therapeutics is a new venture emerging from research carried out over several years by founder Dr Breandan Kennedy with Dr Alison Reynolds at the UCD School of Biomolecular and Biomedical Science and the UCD Conway Institute.

Dr Kennedy said: “It is a great honour for Phision Therapeutics to have won the 2015 UCD VentureLaunch Accelerator Programme and it is a great endorsement for our new venture going forward.

“Looking to the future we are currently seeking €400,000 in seed funding to enable us to formulate and manufacture our novel small molecule drugs. Thereafter, following additional fund raising, we plan to proceed with pre-clinical and clinical studies to validate that our drugs offer a better treatment option, including a reduction in the number of eye injections, for patients experiencing vision loss associated with AMD.”

Funders of this research to date include Enterprise Ireland, Science Foundation Ireland, Irish Research Council, Health Research Board, and the European Commission’s Marie Skłodowska-Curie Actions Programme.

TechCentral Reporters

Read More:

Leave a Reply

Back to Top ↑